We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Cordyceps Sinensis and Lingzhi on Cardiovascular Fitness and Cognitive Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01718548
Recruitment Status : Unknown
Verified October 2012 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : October 31, 2012
Last Update Posted : October 31, 2012
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Cordyceps Sinensis (CS) and Lingzhi extracts have been used in Chinese Medicine for many years for treatment of a variety of conditions. The aim of this study is to evaluate the effects of oral ingestion of CS and Lingzhi extracts of a period of 28 days on cardiopulmonary fitness and cognitive functioning in young, healthy physical education students.

Condition or disease Intervention/treatment
Physical Fitness Executive Function Dietary Supplement: Cordyceps Sinensis (CS) and Lingzhi Dietary Supplement: Tea and Flour

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Study Start Date : December 2012
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: CS and Lingzhi
CS liquid (each dosage is a bottle of liquid containing 30 ml: comprising 75% of CS, 6% Lingzhi, 6% shitake, 5% bamboo shoot, 2% honey, 0.1% potassium sorbet and 5.9% pure water) and Lingzhi capsule (each capsule contains 620mg of: 52.42% Lingzhi, 28.23% CS, and 19.35% soy gel ) ; one quarter bottle of CS to be ingested twice a day, and the Lingzhi capsule to be taken once a day, both for a period of 28 days.
Dietary Supplement: Cordyceps Sinensis (CS) and Lingzhi
Placebo Comparator: Placebo
Liquid tea ingested twice a day and flour-filled capsules ingested once a day over a period of 28 days
Dietary Supplement: Tea and Flour
Placebo


Outcome Measures

Primary Outcome Measures :
  1. Improvement in Cardiopulmonary Fitness after Ingestion of CS and Lingzhi Extracts [ Time Frame: 28 days ]
    Before and after 28-day ingestion of CS and Lingzhi extracts, subjects will undergo a graded exercise test on a treadmill and results will be compared.


Other Outcome Measures:
  1. Effect of CS and Lingzhi on Cognitive Functioning [ Time Frame: 28 days ]
    Before and after 28-day ingestion of CS and Lingzhi the subjects undergo computerized cognitive tests and results will be compared.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Physical education students

Exclusion Criteria:

  • All others
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01718548


Locations
Israel
Wingate Institute Not yet recruiting
Netanya, Israel
Contact: Sharon Tsuk, PhD    09-8639235    sharontsuk1@gmail.com   
Principal Investigator: Sharon Tsuk, PhD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
More Information

Responsible Party: Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT01718548     History of Changes
Other Study ID Numbers: 0062-12-HYMC
First Posted: October 31, 2012    Key Record Dates
Last Update Posted: October 31, 2012
Last Verified: October 2012